Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed)

The summary for the Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed): The purpose of this FOA is to develop and use models to investigate the contribution of synaptic activity and circuit plasticity changes to the progression of disease processes that underlie neurodegeneration in dementia. The overall goal is to understand, from a mechanistic standpoint, the earliest synaptic, circuit and network changes that contribute to AD/ADRD disease onset and pathogenesis. A better in vivo mechanistic understanding of synaptic activity and circuit plasticity changes that underlie the earliest stages of neurodegeneration in AD/ADRD should increase opportunities for developing future interventions. Utilizing technology developed in NIH BRAIN programs is encouraged, including animal-based studies that validate in vivo relevance of findings based on cell-based or organoid-based research. Applications that rely entirely on cell-based or organoid-based systems are out of scope.

Federal Grant Title:	Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-22-059
Type of Funding:	Grant
CFDA Numbers:	93.853, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	February 5th, 2022
Original Application Deadline:	February 5th, 2022
Posted Date:	November 3rd, 2021
Creation Date:	November 3rd, 2021
Archive Date:	March 13th, 2022
Total Program Funding:
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 24th, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-22-059.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Ge...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...; • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...; • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...